Throughout his career in biotechnology, Carsten Thiel has always placed a lot of importance on the concept of ethics in medicine and business. He is currently serving EUSA Pharma as its European President.
Over the years, Carsten Thiel has played a part in the launch of important medications and products like Prolia, Neulasta, Strensiq, and more.
Through the work that he has done, Carsten Thiel has improved the lives of patients suffering from different conditions around the globe. Many of the treatments created by the companies that he was working with are considered medical breakthroughs and many of them treat illnesses in which there had previously been no other options.
In the case of one of the treatments spearheaded by Carsten Thiel, the population that it was designed to help were young children who were dealing with a degenerative bone disease known as hypophosphatasia. While the medication could make a huge difference in the lives of the children being treated, it needed to be given by injection.
Many children are very phobic of needles and Carsten Thiel knew that something had to be done to counter this as it was important the injections be delivered several times a week. They used creative solutions such as the “buddy system” to help these children alleviate some of their fears. See This Page for additional information.
Carsten is dedicated to being able to help people through his work and strives to create humane solutions to problems while showing empathy. He is a native of Berlin Germany and has always done well throughout his education.
He attended the University of Bristol where he earned a Bachelor’s of Science in organic chemistry before eventually earning a Molecular Biology Ph.D. from the Max Planck Institute for Biophysical Chemistry. After graduating, he took a position with the biotechnology firm Hoffman la-Roche and has been moving up in the industry ever since.
Like him on https://www.facebook.com/carsten.thiel.58
EUSA Pharma (EUSA), is a global biopharmaceutical company that focuses on the treatment of oncology and other rare infections. The company was launched in March 2015. With many years of prosperity in delivering world-class products, the company has developed extensive commercial networks in the United States and around Europe, as well as the establishment of direct presence in other selected markets in the world.
EUSA Pharma is managed by a team of focused leaders who have many years of experience as well as recommendable records in developing successful pharmaceutical companies. The company also receives significant financial support from one of the leading life science investor, EW Healthcare Partners.
With the aims of improving the efficiency of service delivery, the company created new positions. It was on 15th May, when the company made the official announcement that it had appointed Dr. Carsten Thiel to fill the position of President in charge of the company’s affair in Europe and Dr. Darrel p. Cohen to take over the new post as the Head of Clinical Development.
Carsten Thiel is a well-known figure in the pharmaceutical and biopharmaceutical professions. Dr. Carsten Thiel, a Ph.D. holder, brings extensive experience of over 27 years gained serving in a variety of international roles in the pharmaceutical industry. Prior to this post, he was serving as the CEO of a US-based company, Abeona Therapeutics, as a gene therapy specialist. He also worked for several years at Alexion Pharmaceutical as the CEO where he led the company’s EMEA, Asia, Pacific, and Australasia organizations.
Carsten Thiel is an authority in biotechnology having spent a good number of years in the industry. He believes that the field has entered its golden age and the future holds a lot of promise. Answers to pertinent human concerns like living disease-free lives are sure to be addressed during this period. See This Page for additional information.
On the other hand, Dr. Darrel P. Cohen is a qualified oncologist specialist with two decades of clinical development experience in the pharmaceutical industry. Before joining EUSA, Dr. Cohen was a Vice President of Pfizer’s International Oncology firm where he led the company with remarkable achievements. He also worked at Duke University in the department of medicine where he served as an Associate Tutor and Oncology Fellow.
View source: http://www.dougsandler.com/news/2019/5/28/curating-a-career-carsten-thiels-purposeful-exploration-of-pharma
Marc Beer has recently been named as Chairman of the Board at a leading healthcare company known as LumeN XT. Beer will be joining a leading company that specializes in developing surgical illumination products. These products will help surgeons and other healthcare professionals more efficiently perform surgical procedures that are minimally invasive. Since being named as the Chairman of the Board at LumeN XT, Marc will bring nearly three decades of experience and expertise to the company. He has spent many years providing solid leadership for healthcare companies as well as participating in the development of pharmaceuticals, medical devices and equipment for making diagnostics.
As soon as he was named as Chairman of the Board at LumeN XT, Marc Beer expressed his outlook on his new position. Beer said that he is very proud to be joining a very well run organization. He has said that he will be honored to work with a group of dedicated surgeons and engineers who have established themselves as leading professionals. With their experience in surgical illumination, they will be able to make valuable contributions to the healthcare industry. Along with expressing his satisfaction in being named as the Chairman of LumeN XT, Marc has also said that the company will help increase the number of surgical procedures that are minimally invasive.
With the recent addition of Marc Beer, the co founder of LumeN XT Paul Rhyne also made a statement. He mentioned that Marc is someone who has been able to demonstrate his expertise with healthcare companies. Marc has been able to lead healthcare companies that were in the growth phase. Under his leadership, these companies were able to become more profitable and expand globally. They were also able to introduce valuable solutions to a number of different health issues as well. With Marc’s accomplishments in mind, LumeN XT will be in position to continue to remain as an innovative company in the healthcare sector.
Marc Beer has had a long and successful career in the healthcare and biotechnology industries. Before he was named as the Chairman of the Board at LumeN XT, Beer was the founder, chairman and chief executive officer of another successful company called Renovia Incorporated. While he was leading Renovia, Marc helped develop diagnostic devices for women who were suffering from pelvic floor disorders. He was also the founder and chairman of the company known as Minerva Neurosciences. While working at this company, Marc helped develop treatments for the nervous system. This included developing treatments for psychological conditions such as depression, schizophrenia and Parkinson’s Disease.
Throughout his career, Marc Beer has been involved in helping many companies become leading enterprises in the healthcare industry. He has held high level executive positions at other healthcare companies. As well as being involved in managing and directing healthcare companies, Marc Beer has also held key positions in governing boards as he was a member of the Biotechnology Industry Organization Emerging Companies Section Governing Board.
Marc beer is an entrepreneur with experience in pharmaceutical, Biotechnology and diagnostic markets. He holds a bachelor of science from the Miami University in Ohio. He is also the co-founder of Renovia group. He serves as a member of the Notre Dame Research and commercialization advisory board. He is also a member of the Miami University Business Advisory Council and the University’s Graduate Studies Research and Advisory committee.
His excellent leadership qualities and innovations enable him to practice business deals that assist people as he is committed to excelling in these businesses. He has created jobs to more than 300 people. He has guided companies that have since been listed in NASDAQ as well as going public.
Just recently Marc Beer was appointed as the chairman of the LumeNXT board. LumeNXT is a private company doing business with the aim of developing proprietary surgical lighting artifacts for simple persistent surgeries. He has over twenty-five years of experience in this industry thus suited for the new appointment as a chairman. LumeNXT boasts of engineers and surgeons that are experienced in the area of surgical illumination. Illumination increases precision, visibility, and flexibility during the surgical operation thus making the innovation helpful in comparison to customary techniques.
The technology offers a platform where illumination is used as a temperature reduction method to enhance surgical accuracy at an affordable cost and ensuring there is enough safety. Marc Beer is tasked with the duty of guiding the LumeNXT Company into positive growth and leading it to worldwide commercial rollout. His also tasked to make sure the company goes into big profits as it grows steadily.
LumeNXT original outlook protects tissues against damage to any high temperatures by incessantly eradicating the heat from the light giving elements. This technology has been of great help to the surgeons as it is more efficient. The company is dedicated to coming up with modified and individualized solutions that are based on values that the customer upholds.
He has also been at the helm of Minerva Neurosciences Company as the chairman of the board. It is a biopharmaceutical company developing products that treat diseases associated with the central nervous system. Before joining Minerva he held positions in the biopharmaceutical industry where he was tasked with launches which were commercial in nature looking into rare diseases in the world, worldwide growth, acquisitions, and IPOs.
Some of Marc Beer such position as a top executive includes the board o Good Start Genetics as its founding chairman, The CEO of Aegerion Pharmaceuticals, CEO of ViaCell, Vice President of Global Marketing at Genzyme as well as the Biotechnology Industry Organization Governing committee. Learn more: https://www.businesswire.com/news/home/20180821005199/en/Renovia-Completes-42.3-Million-Series-Financing
The chairman, CEO, and co-founder of Renovia Inc. has obtained a total of $32 million in a Series B round and a further $10 million for his medical technology startup venture debt. His leadership in this organization is attributed to his experience in the development and commercialization of enterprises in biotechnology and pharmaceutical devices, and diagnostics Marc Beer focuses on developing products that diagnose and treat urinary incontinence, which is a pelvic floor disorder with a potential to affect more than 250 million women.
Leaders in innovation
The FDA approved Leva in April, which is Renovia’s first product. The obtained funding included the participation of the Longwood Fund. This group deals with the healthcare issues that supported Renovia is early in the funding. Perceptive Adviser of New York and Ascension Ventures of Missouri funded the Series B Round. The funding will assist the development and testing of four products for Renovia. Marc Beer intends to come up with a new generation of Leva.
Marc Beer appreciates the funding and says it is an opportunity to share a vision for better diagnosis and treatment for women facing pelvic floor disorders. He hopes to lead the development of the company into combining its innovative and proprietary sensor technologies with digital health platform. The combination of digital health platforms with technological advancements will provide the customers with valuable data and will produce new options for treatment
Marc Beer opines that if there is an increased understanding of the pelvic floor disorder, there is a chance to lower the long-term health care costs.
Marc Beer’s style of dynamic leadership demonstrates his ability to provide workable solutions that satisfy urgent issues. Together with Ramon Iglesias and Yolanda Lorie, they cofounded Renovia in 2016. His energy and vision make his style of leadership ready to take on ventures that benefit their customers. Marc sees a need for a company that addresses urgent issues, which is a reason why he decided to create Renovia.
His interest in the pharmaceutical field focused on sales and marketing, and this was before he went to work at Genzyme. Marc desires to give back to the society, which is why he was at the Mass Life Science Board for the Commonwealth of Massachusetts.
About Marc Beer
Marc Beer is the co-founder, Chief Executive Officer, and chairman of Renovia Inc. he attended Miami University to study a Bachelor of Science in Business and graduated in 1987. Marc has excellent leadership skills in business as well as public areas of responsibility. He worked at OvaScience as a Strategic Consultant. He is also a member of the Joe Andruzzi Cancer Foundation, which provides financial aid to alleviate the economic and emotional stress experienced by cancer patients and their families. Marc Beer is a member of the Miami University Business Advisory Council. Learn more: https://renoviainc.com/